HIV infection may adversely affect clinical response to chloroquine therapy for uncomplicated malaria in children.
Kamya
M R
MR
Makerere University, Kampala, Uganda.
Kigonya
C N
CN
McFarland
W
W
D017088:AIDS-Related Opportunistic Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000627:therapeutic use*; D004338:Drug Combinations; D005500:Follow-Up Studies; D015483:HIV Antibodies / Q000097:blood; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D007223:Infant; D016778:Malaria, Falciparum / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D011739:Pyrimethamine / Q000627:therapeutic use; D013413:Sulfadoxine / Q000627:therapeutic use; D016896:Treatment Outcome; D014454:Uganda
D000962:Antimalarials; D004338:Drug Combinations; D015483:HIV Antibodies; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine